Alkermes plc
ALKSNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 22, 2026 close
- Market cap
- $7.66B
- P/E (TTM)
- 115.91
- Forward P/E
- 226.16
- Dividend yield
- -
- 52-week range
- $27.00$55.67
- Volume (live)
- -
- Avg. volume (3M)
- 2.40M
Alkermes (ALKS) Stock Price & Financial Analysis
Alkermes Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $43.00 - $44.69 |
|---|---|
| 52-Week High | $55.67 |
| 52-Week Low | $27.00 |
| Open | $44.00 |
| Volume (last close) | 1.83M |
| Average Volume (3M) | 2.40M |
| Revenue (TTM) | 1.67B |
|---|---|
| Net Income (TTM) | 66.12M |
| Free Cash Flow (TTM) | 221.65M |
| EPS (TTM) | $0.39 |
| Profit Margin | 3.97% |
| Operating Margin | 7.03% |
| Return on Equity (ROE) | 3.66% |
| Debt to Equity | 0.84 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 7.66B |
|---|---|
| Shares Outstanding | 173.48M |
| P/E Ratio (TTM) | 115.91 |
| Forward P/E | 226.16 |
| Price to Sales (P/S) | 4.60 |
| Price to Book (P/B) | 4.24 |
| EV/EBITDA | 31.98 |
| 50-Day MA | $44.85 |
|---|---|
| 200-Day MA | $39.87 |
| 1-Year Change | +47.07% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Alkermes at a Glance
As of the Oct 22, 2026 close, Alkermes (ALKS) has a market capitalization of $7.66B. The stock trades at 115.9× trailing earnings, 226.2× forward earnings and 4.6× sales. Over the trailing twelve months it earned $66.12M on revenue of $1.67B (a 4.0% profit margin) and generated $221.65M of free cash flow. Revenue grew 10.8% year over year.
As of its latest reported balance sheet, it holds $511.53M in cash and securities against $1.51B of debt, a net debt position of $999.06M.
Alkermes does not currently pay a dividend.
The share price is up 47.1% over the past year. At $44.18 (the Oct 22, 2026 close) it sits within its 52-week range of $27.00 to $55.67, above its 200-day moving average of $39.87.
Based on 18 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $58.77, 33.0% above the Oct 22, 2026 close.
Frequently Asked Questions About Alkermes
What is the current stock price for ALKS?
As of the Oct 22, 2026 close, ALKS stock trades at $44.18. The 52-week range is $27.00–$55.67, with a day range of $43.00–$44.69.
What is the P/E ratio for ALKS?
As of the Oct 22, 2026 close, Alkermes's trailing twelve-month (TTM) P/E ratio is 115.9, meaning investors pay $115.9 for every $1 of annual earnings. The forward P/E is 226.2, reflecting analyst expectations for future earnings. Alkermes operates in the Healthcare sector.
Does ALKS pay dividends?
Alkermes does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for ALKS?
Based on ratings from 18 professional analysts over the last 90 days, the consensus for ALKS is Buy. The average 12-month price target is $58.77, a 33.0% upside from the Oct 22, 2026 close of $44.18.
What is the market cap of ALKS?
As of the Oct 22, 2026 close, Alkermes's market capitalization is $7.66B, classifying it as a mid-cap company. Alkermes operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.